Compare · IRD vs NVO
IRD vs NVO
Side-by-side comparison of Opus Genetics Inc. (IRD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $219.94B, about 795.2x IRD ($276.6M).
- Over the past year, IRD is up 183.5% and NVO is down 28.0% - IRD leads by 211.5 points.
- IRD has been more active in the news (8 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 13 for IRD).
- Company
- Opus Genetics Inc.
- Novo Nordisk A/S
- Price
- $3.36+9.09%
- $49.68+1.85%
- Market cap
- $276.6M
- $219.94B
- 1M return
- -9.80%
- +4.33%
- 1Y return
- +183.54%
- -27.99%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 8
- 5
- Recent ratings
- 13
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IRD
- President Yerxa Benjamin R sold $22,064 worth of shares (7,429 units at $2.97), decreasing direct ownership by 1% to 704,106 units (SEC Form 4) to satisfy withholding tax
- Chief Operating Officer Schachle Joseph K sold $13,653 worth of shares (4,644 units at $2.94), decreasing direct ownership by 2% to 291,440 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Magrath George sold $27,926 worth of shares (9,475 units at $2.95), decreasing direct ownership by 0.54% to 1,731,869 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Gagnon Robert E. sold $22,942 worth of shares (7,783 units at $2.95), decreasing direct ownership by 1% to 584,375 units (SEC Form 4) to cover taxes
- SEC Form 144 filed by Opus Genetics Inc.
- SEC Form 144 filed by Opus Genetics Inc.
- Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
- Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
- Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
- RBC Capital Mkts initiated coverage on Opus Genetics with a new price target
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S